Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biosimilarity of Gan & Lee Insulin Aspart vs NovoLog/NovoRapid in Healthy Males
NCT04237129Phase 1Completed
- Sponsor
- Gan & Lee Pharmaceuticals
- Start
- Aug 2019
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of insulin aspart in type 1 diabetes mellitus (T1D) (3 arms), sponsored by Gan & Lee Pharmaceuticals. Primary endpoints: Area Under the Serum Insulin Concentration-Time Curve from 0 to 12 Hours, Maximum Serum Insulin Concentration and 2 more. Started Aug 2019; status: completed.
02
Drugs
insulin aspart
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT04237129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04237129.